Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. RHÖN-KLINIKUM AG
  6. News
  7. Summary
    RHK   DE0007042301

RHÖN-KLINIKUM AG

(RHK)
  Report
Delayed Xetra  -  11:36 2022-12-02 am EST
15.35 EUR   -0.32%
11/10Transcript : RHÖN-KLINIKUM Aktiengesellschaft, Nine Months 2022 Earnings Call, Nov 10, 2022
CI
11/10RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQ
10/18Rhön-klinikum Aktiengesellschaft : Changes on the Board of Management
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable

05/08/2022 | 08:24pm EST

DGAP-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Letter of Intent
RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable

09-May-2022 / 02:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Board of Management of RHÖN-KLINIKUM AG today assessed the currently ongoing negotiations with the State of Hesse on a follow-up agreement regarding the granting of investment subsidies for the Universitätsklinikum Gießen und Marburg GmbH (UKGM) and corresponding obligations of the company. It is to replace the existing agreement. In view of the course of negotiations to date, the Board of Management concluded that it is doubtful whether the successor arrangement envisaged in the letter of intent (LoI) dated January 14, 2022, can be successfully concluded in the second quarter of 2022 as planned.
Today, the Board of Management has therefore decided to ask the Supervisory Board of RHÖN-KLINIKUM AG as a precautionary measure to approve a termination of the existing agreement of UKGM, the State of Hesse and the universities in Gießen and Marburg from 2017. The termination of the agreement should come into force on December 31, 2022, and would have to be declared in due time by June 30, 2022. The Board of Management feels compelled to take this precautionary step to secure the necessary room for maneuver in the event that the new agreement is not reached in time. The Supervisory Board will decide on the proposed resolution at an extra-ordinary meeting to be convened at short notice.
Regardless, the company remains committed to the contents of the letter of intent dated January 14, 2022, and hopes to conclude a corresponding follow-up agreement by the end of 2022.

09-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1346471

 
End of Announcement DGAP News Service

1346471  09-May-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1346471&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about RHÖN-KLINIKUM AG
11/10Transcript : RHÖN-KLINIKUM Aktiengesellschaft, Nine Months 2022 Earnings Call..
CI
11/10RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQ
10/18Rhön-klinikum Aktiengesellschaft : Changes on the Board of Management
EQ
08/04RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the Second Quarter and Si..
CI
08/04RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
EQ
05/12RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the First Quarter Ended M..
CI
05/12Rhön-klinikum Aktiengesellschaft : Financial year 2022 again marked by COVID-19 pandemic
EQ
05/08Rhön-klinikum Aktiengesellschaft : The Board of Management of RHÖN-KLINIKUM AG considers t..
EQ
03/24RHÖN-KLINIKUM Aktiengesellschaft Reports Earnings Results for the Full Year Ended Decem..
CI
03/24RHÖN-KLINIKUM AG looks back on successful financial year 2021
EQ
More news
Analyst Recommendations on RHÖN-KLINIKUM AG
More recommendations
Financials
Sales 2022 1 455 M 1 526 M 1 526 M
Net income 2022 16,9 M 17,7 M 17,7 M
Net Debt 2022 28,1 M 29,5 M 29,5 M
P/E ratio 2022 61,4x
Yield 2022 -
Capitalization 1 028 M 1 077 M 1 077 M
EV / Sales 2022 0,73x
EV / Sales 2023 0,70x
Nbr of Employees 18 137
Free-Float 7,69%
Chart RHÖN-KLINIKUM AG
Duration : Period :
RHÖN-KLINIKUM AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHÖN-KLINIKUM AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 15,35 €
Average target price 15,00 €
Spread / Average Target -2,28%
EPS Revisions
Managers and Directors
Tobias Kaltenbach Chief Executive Officer
Stefan Stranz Chief Financial Officer
Jan Liersch Chairman-Supervisory Board
Gunther K. Weiß Chief Operating Officer
Georg Schulze-Ziehaus First Deputy Chairman-Supervisory Board